earnings
confidence high
sentiment positive
materiality 0.80
Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability
ALNYLAM PHARMACEUTICALS, INC.
2025-FY EPS reported
$2.33
revenue$3,713,937,000
- Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
- GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.
- Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.
- AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).
- Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle.
item 2.02item 9.01